Ac Immune SA (ACIU) — SEC Filings

Q: What are the key financial highlights for Ac Immune SA?

Key financial highlights for Ac Immune SA are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Ac Immune SA?

Key executives at Ac Immune SA are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Ac Immune SA stock?

Risk factors for Ac Immune SA (ACIU) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Ac Immune SA?

Forward-looking statements and predictions from Ac Immune SA are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Ac Immune SA. Recent 6-K filing on Apr 7, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Ac Immune SA on SEC EDGAR

Overview

Ac Immune SA (ACIU) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Nov 4, 2025: AC Immune SA filed a Form 6-K on November 4, 2025, reporting for the month of November 2025. The filing is a report of a foreign private issuer and is incorporated by reference into several of AC Immune SA's registration statements on Form F-3 and Form S-8. The company is based in Lausanne, Switzerl

Sentiment Summary

Across 33 filings, the sentiment breakdown is: 4 bullish, 28 neutral, 1 mixed. The dominant filing sentiment for Ac Immune SA is neutral.

Filing Type Overview

Ac Immune SA (ACIU) has filed 28 6-K, 2 20-F, 3 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (33)

6-K Filing — 6-K · Apr 7, 2026
6-K Filing — 6-K · Dec 11, 2025
AC Immune SA Files 6-K Report — 6-K · Nov 4, 2025 Risk: low
AC Immune SA filed a Form 6-K on November 4, 2025, reporting for the month of November 2025. The filing is a report of a foreign private issuer and is incorpora
AC Immune SA Cuts Workforce by 30% to Focus on Key Assets — 6-K · Sep 4, 2025 Risk: medium
On September 4, 2025, AC Immune SA announced a strategic review resulting in a sharpened focus on its key assets, including three clinical-stage immunotherapy p
AC Immune SA Files 6-K Report — 6-K · Aug 5, 2025 Risk: low
AC Immune SA filed a Form 6-K on August 5, 2025, reporting for the period ending June 30, 2025. The filing is a report of a foreign private issuer and is incorp
AC Immune SA Holds Annual Shareholder Meeting, Votes on Agenda Items — 6-K · Jun 20, 2025 Risk: low
On June 19, 2025, AC Immune SA held its Annual General Meeting of Shareholders. The company announced the final voting results on the agenda items, with the Man
AC Immune Appoints Interim EVP of Development — 6-K · Jun 11, 2025 Risk: low
AC Immune SA announced the appointment of Dr. Günther Staffler as interim Executive Vice President, Development, effective immediately. Dr. Staffler, who joined
AC Immune SA Announces 2025 AGM Details and Board Changes — 6-K · May 19, 2025 Risk: low
AC Immune SA announced its 2025 Annual General Meeting (AGM) invitation and proxy card on May 19, 2025, for the meeting scheduled on June 19, 2025. The company
AC Immune SA Files April 2025 6-K Report — 6-K · Apr 30, 2025 Risk: low
AC Immune SA filed a Form 6-K on April 30, 2025, reporting for the month of April 2025. This filing is incorporated by reference into their existing registratio
AC Immune SA Files March 2025 6-K with Press Release and 2024 Report — 6-K · Mar 13, 2025 Risk: low
AC Immune SA filed a Form 6-K on March 13, 2025, reporting its activities for March 2025. The filing includes a press release dated March 13, 2025, and its 2024
AC Immune SA Files 20-F for FY 2024 — 20-F · Mar 13, 2025 Risk: medium
AC Immune SA filed its 20-F report for the fiscal year ending December 31, 2024. The company, incorporated in V8 and headquartered at EPFL Innovation Park, Laus
AC Immune SA Announces Key Executive Promotions — 6-K · Dec 18, 2024 Risk: low
AC Immune SA announced on December 18, 2024, the internal promotions of three key employees, effective January 1, 2025. Mark Danton will become Executive Vice P
SC 13G/A Filing — SC 13G/A · Dec 13, 2024
AC Immune SA Reports Interim Data for Down Syndrome Trial — 6-K · Dec 10, 2024 Risk: medium
On December 10, 2024, AC Immune SA announced interim safety and tolerability data from its ABATE Phase 1b/2 trial for ACI-24.060, an immunotherapy targeting amy
AC Immune SA Reports Positive Phase 2 Parkinson's Trial Data — 6-K · Nov 14, 2024 Risk: medium
On November 14, 2024, AC Immune SA announced positive interim safety and immunogenicity data from its Phase 2 VacSYn clinical trial for ACI-7104.056, an anti-al
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
AC Immune SA Files Form 6-K for November 2024 — 6-K · Nov 5, 2024 Risk: low
AC Immune SA filed a Form 6-K on November 5, 2024, reporting for the month of November 2024. This filing is a report of a foreign private issuer and will be inc
AC Immune Appoints New Chief Medical Officer — 6-K · Sep 19, 2024 Risk: low
On September 19, 2024, AC Immune SA announced the appointment of Dr. Anke Post, MD PhD, as its new Chief Medical Officer (CMO) and a member of the Executive Com
AC Immune to Receive CHF 24.6M Milestone from Janssen — 6-K · Sep 17, 2024 Risk: medium
On September 17, 2024, AC Immune SA announced it will receive a second milestone payment of CHF 24.6 million from Janssen Pharmaceuticals, Inc. This payment is
AC Immune Partner LMI Gets FDA Fast Track for Tau PET Diagnostic — 6-K · Aug 28, 2024 Risk: medium
On August 28, 2024, AC Immune SA announced that its partner, Life Molecular Imaging (LMI), received U.S. FDA Fast Track Designation for the Tau PET diagnostic,
AC Immune SA Files 6-K Report — 6-K · Aug 6, 2024 Risk: low
AC Immune SA filed a Form 6-K on August 6, 2024, reporting for the period ending June 30, 2024. The filing is a report of a foreign private issuer and is incorp
AC Immune SA Replaces ATM Program with Jefferies LLC — 6-K · Aug 6, 2024 Risk: low
On August 6, 2024, AC Immune SA entered into a new Open Market Sales Agreement with Jefferies LLC, replacing its previous at-the-market program. This agreement
AC Immune Unveils Novel Neurodegenerative Drug Candidates — 6-K · Jul 31, 2024 Risk: medium
On July 31, 2024, AC Immune SA announced the unveiling of morADC, a new class of drug candidates for neurodegenerative diseases. This announcement was made via
AC Immune's Alzheimer's Drug JNJ-2056 Gets FDA Fast Track — 6-K · Jul 25, 2024 Risk: medium
On July 25, 2024, AC Immune SA announced that its active-immunotherapy candidate, JNJ-2056 (formerly ACI-35.030), targeting phosphorylated Tau (pTau) for Alzhei
AC Immune SA Holds Annual Meeting, Updates Shareholders — 6-K · Jun 20, 2024 Risk: low
On June 20, 2024, AC Immune SA held its Annual General Meeting of Shareholders. The company provided an operational update and announced the final voting result
AC Immune SA Files 6-K for Shareholder Meetings — 6-K · May 21, 2024 Risk: low
AC Immune SA filed a Form 6-K on May 21, 2024, announcing an invitation to its Ordinary Shareholders' Meeting and its 2024 Annual General Meeting. The filing de
AC Immune SA Files Form 6-K with SEC — 6-K · May 13, 2024 Risk: low
AC Immune SA filed a Form 6-K on May 13, 2024, reporting information as a foreign private issuer. The filing is incorporated by reference into several of their
AC Immune Grants Takeda Option for ACI-24.060 — 6-K · May 13, 2024 Risk: medium
On May 13, 2024, AC Immune SA entered into an Option and License Agreement with Takeda Pharmaceuticals, USA, Inc. This agreement grants Takeda an option to obta
AC Immune SA Files 6-K, Includes 2023 Annual Report — 6-K · Mar 14, 2024 Risk: low
AC Immune SA filed a Form 6-K on March 14, 2024, to report its 2023 Annual Report and a press release dated March 14, 2024. The filing includes information abou
AC Immune SA Files 20-F Annual Report for Fiscal Year Ended December 31, 2023 — 20-F · Mar 14, 2024 Risk: medium
AC Immune SA (ACIU) filed a Foreign Annual Report (20-F) with the SEC on March 14, 2024. AC Immune SA filed its 20-F annual report for the fiscal year ending De
AFFiRiS AG in Liqu Maintains 6.58M Share Stake in AC Immune SA — SC 13G/A · Feb 9, 2024 Risk: low
AFFiRiS AG in Liqu, an Austrian company, filed an amendment to its Schedule 13G, indicating it still beneficially owns 6,578,100 Common Shares of AC Immune SA a
AC Immune Regains Full Rights to Alzheimer's Drugs Crenezumab, Semorinemab — 6-K · Jan 22, 2024
AC Immune SA announced on January 22, 2024, the termination of two research collaboration and license agreements with Genentech, Inc. and F-Hoffman La-Roche Ltd
AC Immune Updates Phase 2 Alzheimer's & Parkinson's Trials — 6-K · Jan 3, 2024
AC Immune SA, a Swiss biopharmaceutical company, filed a 6-K on January 3, 2024, providing a progress update on its Phase 2 active immunotherapy clinical pipeli

Risk Profile

Risk Assessment: Of ACIU's 27 recent filings, 0 were flagged as high-risk, 10 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

Dr. Günther Staffler
Andrea Pfeifer
Mark Danton
Dr. Günther Staffler, PhD
Dr. Francesca Capotosti, PhD
Dr. Anke Post, MD PhD
Christopher Roberts

Top Tags

sec-filing (5) · 6-K (4) · drug-development (4) · foreign-private-issuer (4) · corporate-governance (4) · press-release (4) · shareholder-meeting (3) · annual-report (3) · biotech (3) · agm (2)

Key Numbers

Workforce Reduction: 30% — Indicates a significant restructuring to streamline operations and focus resources.
Fiscal Year End: 2024-12-31 — The report covers the period ending on this date.
Filing Date: 2025-03-13 — The date the 20-F was officially filed with the SEC.
Central Index Key: 0001651625 — Unique identifier for AC Immune SA in the SEC system.
Milestone Payment: CHF 24.6M — Received from Janssen for trial progress
Public Document Count: 161 — Total number of documents in the filing
SEC File Number: 001-37891 — AC Immune SA's SEC file number
Common Shares: 6,578,100 — The total number of AC Immune SA shares beneficially owned by AFFiRiS AG in Liqu, indicating a significant, stable stake.

Forward-Looking Statements

{"claim":"AFFiRiS AG in Liqu will maintain its significant stake in AC Immune SA for the foreseeable future.","entity":"AFFiRiS AG in Liqu","targetDate":"2025-02-09","confidence":"medium"}

Related Companies

JNJ

Frequently Asked Questions

What are the latest SEC filings for Ac Immune SA (ACIU)?

Ac Immune SA has 33 recent SEC filings from Jan 2024 to Apr 2026, including 28 6-K, 3 SC 13G/A, 2 20-F. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of ACIU filings?

Across 33 filings, the sentiment breakdown is: 4 bullish, 28 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Ac Immune SA SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Ac Immune SA (ACIU) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Ac Immune SA?

Financial highlights for Ac Immune SA are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for ACIU?

The investment thesis for ACIU includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Ac Immune SA?

Key executives identified across Ac Immune SA's filings include Dr. Günther Staffler, Andrea Pfeifer, Mark Danton, Dr. Günther Staffler, PhD, Dr. Francesca Capotosti, PhD and 2 others.

What are the main risk factors for Ac Immune SA stock?

Of ACIU's 27 assessed filings, 0 were flagged high-risk, 10 medium-risk, and 17 low-risk.

What are recent predictions and forward guidance from Ac Immune SA?

Recent forward-looking statements from Ac Immune SA include guidance on {"claim":"AFFiRiS AG in Liqu will maintain its significant stake in AC Immune SA for the foreseeable future.","entity":".